performance of pd-l1 ihc assays in impassion130: a post-hoc analysis
Published 5 years ago • 178 plays • Length 4:46Download video MP4
Download video MP3
Similar videos
-
4:27
analysis of impassion130: pd-l1 testing in advanced tnbc
-
1:38
optimal application of pd-l1 ihc tests
-
18:58
pd-l1 testing by immunohistochemistry
-
6:56
all you need to know about pd-l1 by immunohistochemistry
-
4:15
pathologists and pd-l1
-
27:53
navigating challenges with pd-l1 combined positive score (cps)
-
9:53
immunohistochemistry protocol for paraffin embedded tissue sections
-
1:02:49
pd-l1/pd-1 cancer immunotherapy and new targets - gordon freeman, phd
-
27:58
pd-l1 testing considerations
-
3:18
pd-l1 test | clinical significance of pd-l1 test | dr. somashekhar s p | aster labs
-
1:38
combined analyses of pd-l1 and tils for therapy selection in tnbc
-
7:08
impassion130: results of atezolizumab plus nab-paclitaxel for frontline tnbc
-
6:56
impassion130 trial data on pd-l1 tumors in tnbc
-
2:49
nsclc: the increasing need for pd-l1 testing
-
10:20
pd-l1 testing in advanced lung cancer
-
3:37
case 3: pd-l1 testing used in triple-negative breast cancer
-
0:54
dr. o’donnell on challenges with pd-l1 testing in bladder cancer
-
1:25
pd-1 and pd-l1 expression in esophageal and gastric cancer
-
1:55
dr. hirsch on value of pd-l1 testing in patients with lung cancer
-
2:53
comparison of three different pd-l1 diagnostic tests shows a high degree of concordance
-
3:32
value of pd-l1 testing in metastatic urothelial cancer
-
4:25
pd-1/pd-l1 inhibitors explored across nsclc settings